Osteoarthritis and the Complement Cascade.

IF 1.9 Q2 ORTHOPEDICS Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders Pub Date : 2018-01-03 eCollection Date: 2018-01-01 DOI:10.1177/1179544117751430
Sandeep Silawal, Jakob Triebel, Thomas Bertsch, Gundula Schulze-Tanzil
{"title":"Osteoarthritis and the Complement Cascade.","authors":"Sandeep Silawal, Jakob Triebel, Thomas Bertsch, Gundula Schulze-Tanzil","doi":"10.1177/1179544117751430","DOIUrl":null,"url":null,"abstract":"<p><p>Accumulating evidence demonstrates that complement activation is involved in the pathogenesis of osteoarthritis (OA). However, the intimate complement regulation and cross talk with other signaling pathways in joint-associated tissues remain incompletely understood. Recent insights are summarized and discussed here, to put together a more comprehensive picture of complement involvement in OA pathogenesis. Complement is regulated by several catabolic and inflammatory mediators playing a key role in OA. It seems to be involved in many processes observed during OA development and progression, such as extracellular cartilage matrix (ECM) degradation, chondrocyte and synoviocyte inflammatory responses, cell lysis, synovitis, disbalanced bone remodeling, osteophyte formation, and stem cell recruitment, as well as cartilage angiogenesis. In reverse, complement can be activated by various ECM components and their cleavage products, which are released during OA-associated cartilage degradation. There are, however, some other cartilage ECM components that can inhibit complement, underlining the diverse effects of ECM on the complement activation. It is hypothesized that complement might also be directly activated by mechanical stress, thereby contributing to OA. The question arises whether keeping the complement activation in balance could represent a future therapeutic strategy in OA treatment and in the prevention of its progression.</p>","PeriodicalId":10443,"journal":{"name":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","volume":"11 ","pages":"1179544117751430"},"PeriodicalIF":1.9000,"publicationDate":"2018-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/82/10.1177_1179544117751430.PMC5805003.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179544117751430","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Accumulating evidence demonstrates that complement activation is involved in the pathogenesis of osteoarthritis (OA). However, the intimate complement regulation and cross talk with other signaling pathways in joint-associated tissues remain incompletely understood. Recent insights are summarized and discussed here, to put together a more comprehensive picture of complement involvement in OA pathogenesis. Complement is regulated by several catabolic and inflammatory mediators playing a key role in OA. It seems to be involved in many processes observed during OA development and progression, such as extracellular cartilage matrix (ECM) degradation, chondrocyte and synoviocyte inflammatory responses, cell lysis, synovitis, disbalanced bone remodeling, osteophyte formation, and stem cell recruitment, as well as cartilage angiogenesis. In reverse, complement can be activated by various ECM components and their cleavage products, which are released during OA-associated cartilage degradation. There are, however, some other cartilage ECM components that can inhibit complement, underlining the diverse effects of ECM on the complement activation. It is hypothesized that complement might also be directly activated by mechanical stress, thereby contributing to OA. The question arises whether keeping the complement activation in balance could represent a future therapeutic strategy in OA treatment and in the prevention of its progression.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨关节炎与补体级联。
越来越多的证据表明,补体激活与骨关节炎(OA)的发病机制有关。然而,人们对补体在关节相关组织中的密切调控以及与其他信号通路的交叉对话仍不甚了解。本文总结并讨论了最近的研究成果,以便更全面地了解补体参与骨关节炎发病机制的情况。补体受多种分解代谢和炎症介质的调控,在 OA 中发挥着关键作用。它似乎参与了在 OA 发生和发展过程中观察到的许多过程,如细胞外基质(ECM)降解、软骨细胞和滑膜细胞炎症反应、细胞溶解、滑膜炎、骨重塑失衡、骨质增生形成、干细胞募集以及软骨血管生成。相反,补体可被各种 ECM 成分及其裂解产物激活,这些成分在 OA 相关软骨降解过程中释放出来。然而,还有一些软骨 ECM 成分可以抑制补体,这凸显了 ECM 对补体激活的不同影响。据推测,机械应力也可能直接激活补体,从而导致 OA。问题在于,保持补体激活的平衡是否可能成为未来治疗 OA 和预防其恶化的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.40
自引率
0.00%
发文量
14
审稿时长
8 weeks
期刊最新文献
Is CRPS-1 a Chronic Disabling Disease? A Long-term, Real-Life Study on Patients Treated With Neridronate. The Impact of Tobacco Smoking on Systemic Sclerosis, Idiopathic Inflammatory Myositis, and Systemic Lupus Erythematosus. Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus. Good Short- and Mid-term Outcome After Cross-Linked Hyaluronic Acid Infiltration for Hallux Rigidus: A Case Report. Idiopathic Granulomatous Mastitis, Erythema Nodosum, and Polyarthritis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1